Get the Daily Brief
Latest Biotech News
FDA clears topical pan‑JAK Anzupgo for chronic hand eczema
The FDA approved delgocitinib (Anzupgo®), a topical pan‑JAK inhibitor, for adults with chronic hand eczema who failed topical corticosteroids or cannot use them. Regulators emphasized the topical...
Enterococcus faecalis uses extracellular electron transport to stall wound repair
An NTU Singapore–University of Geneva team published in Science Advances that Enterococcus faecalis uses extracellular electron transport (EET) to generate reactive oxygen species, activate the...
Dormant metastases soften to evade immune mechanosurveillance – MSK uncovers TGFβ‑linked EMT shift
Researchers at Memorial Sloan Kettering showed in Nature Cancer that disseminated lung adenocarcinoma cells can undergo a TGFβ‑driven atypical epithelial‑to‑mesenchymal transition (EMT) that ends...
Fratricide‑driven unedited CD7 CAR‑T shows activity in T‑cell leukemia
A study in the Journal of Translational Medicine reported that fratricide‑driven, unedited CD7 CAR‑T cells produced anti‑leukemic activity in preclinical models of T‑cell leukemia. The approach...
ImmunityBio CAR‑NK Delivers Durable Complete Responses – Waldenström’s Trial
ImmunityBio reported durable complete responses in early data from an allogeneic, off‑the‑shelf CD19 CAR‑NK program combined with rituximab in patients with Waldenström’s non‑Hodgkin lymphoma. The...
Epkinly Fails to Extend Survival – AbbVie, Genmab
AbbVie and Genmab disclosed that Epkinly (their anti‑CD47/PD‑1 program or other named asset in a late‑stage study) did not prolong overall survival in a Phase 3 trial for diffuse large B‑cell...
UC San Diego Wins ARPA‑H Grant: $25.8M to 3D‑Print Patient Livers
UC San Diego secured an ARPA‑H award of up to $25,771,771 over 60 months to develop patient‑specific, 3D‑bioprinted human livers intended as an alternative to donor transplantation. The...
FDA Clears Topical JAK Inhibitor for Hand Eczema – Anzupgo Approval
The FDA approved delgocitinib (Anzupgo®), a topical pan‑JAK inhibitor, for adults with chronic hand eczema (CHE) who have inadequate response to topical corticosteroids or cannot use them....
Foli Bio Tests Stool RNA to Monitor IBD, Predict Drug Response
Columbia University spinout Foli Bio is developing stool‑based RNA‑seq panels that use exfoliated fecal RNA to predict drug response and monitor inflammatory bowel disease (IBD), with the stated...
Destina Genomica Wins €2.2M to Advance Drug‑Induced Liver Injury Assay
Spanish diagnostics firm Destina Genomica received €2.2 million from the European Innovation Council (EIC) to accelerate clinical transition of its LiverAce Combo assay for drug‑induced liver...
Legal Scrutiny Grows Over FDA’s New Expedited Drug Program: Who Signs Off?
Reporting shows internal unease at the FDA about a new expedited drug program after staff described instances where usual review steps were bypassed and senior leaders were reluctant to sign off...
Novo Nordisk Foundation Pledges Up to $850M to Scale European Biotech
The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s reach from Denmark to startups across Europe. The funding aims to expand early‑stage support,...
Conference Week Drives Fresh Capital Into Biotech — Finance Report
BioCentury reported an uptick in biotech financing tied to JP Morgan Healthcare Conference week, with multiple new funds and financings announced, including activity from Arkin, Lux, a16z and...
AI‑Designed Antibodies Act as Live‑Cell Probes — Colorado State Team
Researchers at Colorado State University reported using artificial intelligence to redesign antibodies so they behave as fluorescent probes that reveal activity inside living cells, enabling...
ImmunityBio’s off‑the‑shelf CAR‑NK posts durable complete responses – Waldenström’s data
ImmunityBio disclosed early clinical results showing durable complete responses in patients with Waldenström’s macroglobulinemia treated with its allogeneic CD19 CAR‑NK cells plus rituximab. The...
ARPA‑H backs UC San Diego’s bid to 3D‑print patient livers – $25.8M award
UC San Diego received an ARPA‑H award — up to $25.77 million over 60 months — to develop patient‑specific, 3D‑bioprinted human livers under the PRINT program. The multidisciplinary project will...
AbbVie, Genmab’s Epkinly fails to extend overall survival in DLBCL – Phase 3 miss
AbbVie and Genmab announced that Epkinly (tucatinib? or Epkinly—company‑reported agent) did not prolong overall survival in a Phase 3 study for diffuse large B‑cell lymphoma (DLBCL). The...
Vedanta cuts headcount, pivots resources to VE303 phase 3 – layoffs to focus on C. difficile program
Vedanta Biosciences said it significantly reduced staff to concentrate remaining resources on its lead live‑biotherapeutic candidate VE303, now positioned for a Phase 3 study in recurrent...
NTU, Geneva identify E. faecalis redox mechanism that blocks wound healing – new therapeutic target
An international team led by Nanyang Technological University and the University of Geneva reported that Enterococcus faecalis impairs chronic wound healing by generating reactive oxygen species...
Foli Bio developing stool RNA‑seq panels to predict IBD response — noninvasive monitoring aim
Columbia University spinout Foli Bio is developing exfoliated fecal RNA sequencing panels intended to predict drug response in inflammatory bowel disease (IBD) patients and potentially replace...